Neurocrine Biosciences
NBIX
NBIX
391 hedge funds and large institutions have $9.56B invested in Neurocrine Biosciences in 2019 Q4 according to their latest regulatory filings, with 109 funds opening new positions, 137 increasing their positions, 103 reducing their positions, and 41 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more capital invested
Capital invested by funds: $ → $
18% more funds holding
Funds holding: 332 → 391 (+59)
14% more funds holding in top 10
Funds holding in top 10: 7 → 8 (+1)
1.37% less ownership
Funds ownership: 98.02% → 96.65% (-1.4%)
Holders
391
Holding in Top 10
8
Calls
$93.9M
Puts
$56.8M
Top Buyers
| 1 | +$79M | |
| 2 | +$70.5M | |
| 3 | +$67.3M | |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$60.3M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
+$35.1M |
Top Sellers
| 1 | -$141M | |
| 2 | -$121M | |
| 3 | -$73.8M | |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$70.4M |
| 5 |
O
OrbiMed
New York
|
-$68.7M |